ItalyItaly

MolMed and GSK fight bubble boy

01.08.2011

Milan/London – Italy’s MolMed SpA has signed a deal with UK-based pharmaceutical giant GlaxoSmithKline to develop a production process for a gene therapy against the rare ‘bubble boy disease’. Over the next two years, GSK will pay the Italian biotech up to EUR5.5m to work on the candidate against ADA-SCID (Adenosine Deaminase Deficiency – Severe Combined Immune Deficiency). The life-threatening disease affects approximately 350 children worldwide. ADA-SCID is caused by a mutation in a single gene that prevents the body from producing the ADA enzyme. In the treatment, which GSK acquired from San Raffaele Telethon Institute in October 2010, the faulty gene is repaired in stem cells derived from the patient’s bone marrow. Previous studies suggest the treatment is able to restore long-term immune function and protect children with ADA-SCID against severe infections. The job is very welcome at MolMed. The Milan-based biotech is still hemor­rhaging money. In the first half of 2011, the firm’s EUR1.3m in revenues were dwarfed by its EUR11.8m in operating costs – and outlay won’t drop anytime soon. In late July, MolMed announced the enrolment of the first patient in a randomised Phase II trial of its investigational anticancer drug NGR-hTNF for the treatment of platinum-resistant/refractory ovarian cancer.

ItalyItaly

12.06.2011

Milan – Everyone agrees that Italy is not Greece, but it is common wisdom that the country could also be doing better. Considering the meagre growth of the Italian economy in the last decade however, data fom the 2011 survey of...

ItalyItaly

01.04.2011

Milan – Italian drugmaker Newron Pharmaceuticals S.p.A. and Merck Serono have broadened the scope of their 5-year-old collaboration on CNS drugs. In addition to the Parkinson’s treatment safinamide, under the terms of a new...

ItalyItaly

16.02.2011

Milan/Berlin – Swiss-Italian biotech Philogen SpA has revoked its plan to sell a 23% stake worth EUR65.3m and go public on the Milan stock exchange this Friday. The move came after German Bayer HealthCare unexpectedly terminated...

ItalyItaly

06.02.2011

Rome – The EUR2.5m ERC Advanced Grants are the Grammies of European science – not in the same league as a Nobel Prize, but still a lucrative honor. In the fourth round since 2007, the European Research Council awarded some a590m...

ItalyItaly

29.11.2010

Modena/London – Researchers from Germany, Italy and the UK have identified a molecule that is key to the onset of addiction and also involved into memory formation (EMBO Journal, doi:10.1038/emboj.2010.279). According to results...

ItalyItaly

09.11.2010

Genoa/Philadelphia — The inexpensive anti-gout drug allopurinol can counteract colorectal adenoma progression, according to data presented yesterday at the 9th Annual AACR Frontiers in Cancer Prevention Research Conference...

Displaying results 11 to 20 out of 181

< Previous 11-20 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-italy/browse/1/article/molmed-and-gsk-fight-bubble-boy.html

Video

All videos

Product of the week

Products

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Events

All Events

Partner-Events

München

BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes

TOP

  • MEDIGENE14.50 EUR9.19%
  • SARTORIUS143.75 EUR7.28%
  • FORMYCON31.50 EUR4.06%

FLOP

  • THERAMETRICS0.08 CHF-11.11%
  • CO.DON2.90 EUR-7.94%
  • 4SC1.25 EUR-6.72%

TOP

  • MEDIGENE14.50 EUR117.4%
  • 4SC1.25 EUR76.1%
  • FORMYCON31.50 EUR39.9%

FLOP

  • CYTOS1.27 CHF-15.3%
  • BB BIOTECH280.70 EUR-11.5%
  • MORPHOSYS62.50 EUR-10.2%

TOP

  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.27 CHF647.1%
  • FORMYCON31.50 EUR343.7%

FLOP

  • MOLOGEN5.02 EUR-53.5%
  • BIOFRONTERA2.60 EUR-20.2%
  • THERAMETRICS0.08 CHF-20.0%

No liability assumed, Date: 17.04.2015

Current issue

All issues